What an exciting year in stem cell science and translational medicine! STEM CELLS Translational Medicine (SCTM) and its sister journal, STEM CELLS (www.Stemcells.Com, @StemCellsJournal), with its focus on a better understanding of stem cell function, continued to publish remarkable, groundbreaking findings that are moving the field forward. And, in the regulatory arena, the U.S. Food and Drug Administration began implementing the 21st Century Cures Act, designed to bring new treatments, including regenerative medicine, to patients more quickly and efficiently. Just in the past few months, the agency issued important guidance documents designed to provide a clear pathway to scientists who are developing therapies in the field.
The field is now at a tipping point. While the science is relatively new and numerous challenges remain, there has been enough progress to warrant a new focus on how to efficiently and costeffectively bring new treatments to patients. Just as advanced manufacturing changed the face of the auto industry, so must regenerative medicine turn to the practical considerations of producing its products on a mass scale. To ensure that regenerative medicine therapies are one day commonplace, this focus on manufacturing must happen now, even as we grapple with the fields remaining scientific challenges.
We are pleased to report that SCTM is taking a leadership role in this arena in collaboration with the Regenerative Medicine Manufacturing Society and the addition of a new section dedicated to this area. Now, in addition to turning to this journal for the latest advances in clinical translational medicine, you also can expect to learn how scientists around the world are advancing regenerative medicine manufacturing. You will see reports of breakthroughs in areas such as:
Manufacturing for Regenerative Medicine GMP aspects Cell-based processing/expansion Cell-based potency/storage Quality assurance/control Scale-up and production Cell-based therapies release criteria Regulations for manufacturing With this new section, complementing the high-caliber research that SCTM has a reputation for publishing, the journal is truly a leader in the field of regenerative medicine. As an example of the research published in SCTM, below we highlight the top five "most accessed" articles during 2017, viewed or downloaded a total of almost 30,000 times, as well as those with the highest Altmetric scores, with an average score of 462. Altmetric scores track where research is shared and discussed online. SCTM is proud to have published research from around the world pointing to potential new treatments for a wide range of diseases affecting the population, from Parkinson's disease and diabetes to cerebral palsy and autism. This is an open access article under the terms of the Creative Commons Attribution-NonCommercialNoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. SCTM's publisher, AlphaMed Press, and its leaders Ann and Martin Murphy, should be commended for their vision and for the work that their dedicated staff does daily to bring these highquality publications to our readers. A special thanks goes to our Senior Editors Paolo De Coppi, Geoffrey Gurtner, Douglas Losordo, Alan Trounson, and Rocky Tuan and our distinguished editorial board members who work hard to make sure the best papers can be accepted.
TOP ACCESSED ARTICLES
We are grateful to each and every one of you who has played a role in SCTM attaining a leadership role in the field. We are especially thankful to our contributors who are doing exceptional work. We look forward to reviewing your work in 2018 and especially to seeing advances made in the manufacturing arena. And to our readers, we thank you for continuing to come back to the journal for the latest advances in the field. All of us at SCTM are expecting another successful year in 2018 and we offer best wishes to each of you.
Anthony Atala, M.D., Editor-in-Chief
